The Medicines Company and Alnylam Pharmaceuticals Announce Initiation of Phase III Clinical Trials of Inclisiran

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. SPCX
2. FDX
3. META
4. ABBV
5. SPY
6. BLZE
7. IBM
8. NKE
9. MU
10. ACN

Go back to The Medicines Company and Alnylam Pharmaceuticals Announce Initiation of Phase III Clinical Trials of Inclisiran

Alnylam Pharmaceuticals (ALNY) PT Raised to $107 at Stifel

November 8, 2017 10:07 AM EST

Stifel raised its price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $107.00 (from $83.00) while maintaining a Hold rating following non-eventful earnings.

Analyst Stephen Willey views the initiation of the P3 ENVISION trial as an incremental positive.

... More